Study Details

Back to Search Results

A Study to Evaluate Enfortumab Vedotin in Subjects with Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

Recruitment complete
The study is ongoing, and participants are receiving an intervention or being examined, but potential participants are not currently being recruited or enrolled.

Clinicaltrials.gov ID

The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
NCT04225117

Astellas Study ID

The unique identification code given by the study sponsor.

7465-CL-202

EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).

N/A

Follow Trial

Condition

Advanced/Metastatic Cancer

Phase

These clinical trials are done to learn if an experimental treatment helps participants who have a specific condition or disease. Phase 2 trials usually include a larger group of participants than Phase 1 trials.

Phase 2

Age

18 Years - N/A

Sex

Female & Male

Product

enfortumab vedotin

Type

A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

Interventional

Trial Dates

Mar 2020 - Sep 2026

Masking

None (Open Label)

Enrollment number

320

An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects with Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

Study summary

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for A Study to Evaluate Enfortumab Vedotin in Subjects with Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

Locations

Site JP81002

Koto, Japan

Gettysburg Cancer Center

Gettysburg, United States, 17375

Seattle Cancer Care Alliance

Seattle, United States, 98109

Site JP81004

Nagoya, Japan

Site JP81003

Chuo, Japan

New York University Langone Health

New York, United States, 10016

Piedmont Hospital

Atlanta, United States, 30318

Site JP81001

Kashiwa, Japan

Mary Crowley Research Center

Dallas, United States, 75230

Arizona Oncology

Tucson, United States, 85711

University of Kansas

Fairway, United States, 66205

Site JP81006

Nagaizumi, Japan

University of Colorado

Aurora, United States, 80045

Comprehensive Cancer Centers of Nevada

Las Vegas, United States, 89169

Indiana University Cancer Center

Indianapolis, United States, 46202

University of Southern California

Los Angeles, United States, 90033

Washington University in St. Louis

St. Louis, United States, 63110

University of Michigan

Ann Arbor, United States, 48109

Florida Cancer Specialists

Tallahassee, United States, 32308

Northside Hospital

Atlanta, United States, 30342

Northwestern University Medical Center

Chicago, United States, 60611

Ohio State University

Columbus, United States, 43210

Cleveland Clinic

Cleveland, United States, 44195

Nebraska Methodist Hospital

Omaha, United States, 68114

Wisconsin Carbone Cancer Center

Madison, United States, 53792

Florida Cancer Specialists

West Palm Beach, United States, 33401

Florida Cancer Specialists

Fort Myers, United States, 33901

Site JP81005

Chuo-ku, Japan

Henry Ford Hospital

Detroit, United States, 48202

Rutgers Cancer Institute

New Brunswick, United States, 08901

University of Chicago

Chicago, United States, 60637

Dana-Farber Cancer Institute

Boston, United States, 02215

University of Texas

Houston, United States, 77030

Ochsner Medical Center

New Orleans, United States, 70121

Site CA15001

Hamilton, Canada, L8V 5C2

Site CA15003

Ottawa, Canada, K1H 8L6

University of Minnesota Cancer Center

Minneapolis, United States, 55455

Dartmouth-Hitchcock Norris Cotton Cancer Center

Lebanon, United States, 03765

Sarah Cannon Research Institute

Nashville, United States, 37203

University of Cincinnati

Cincinnati, United States, 45219

Site JP81007

Osaka-Sayama, Japan

Memorial Sloan Kettering Cancer Center

New York, United States, 10022

Site CA15002

Vancouver, Canada, V5Z 4E6

Providence St. Joseph Medical Center

Burbank, United States, 91505

Site JP81009

Shinjuku-ku, Japan

Site JP81010

Okayama, Japan

Site JP81011

Kitaadachi-Gun, Japan

University of Nebraska

Omaha, United States, 68198

Site CA15005

Montreal, Canada, H3T 1E2

University of California - San Francisco

San Francisco, United States, 94158

Beth Israel Deaconess Medical Center

Boston, United States, 02215

The purpose of this website is to offer education and information to patients and their families and friends, the public, and healthcare professionals about the clinical trial process. In addition, the website will provide specific information about Astellas clinical trials. Please read the complete Astellas Transparency Policy to learn about the clinical trial information available on this website

© ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.

POWERED BY:

Pharma Intelligence logo